araag2/HINT huggingface dataset:
Clinical trial NCT00254566 (phase 3, status: completed)
Conditions: chronic bronchitis
ICD codes: J41.0, J41.1, J42, J41.8, J40
Drugs: moxifloxacin, azithromycin sr
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of chronic bronchitis (chronic cough and sputum production on most days for
             three consecutive months for more than two consecutive years) and clinical evidence of
             AECB as demonstrated by both the following symptoms:

          -  Production of purulent sputum as defined by Gram stained sputum specimen

          -  Presence of all of the following:

          -  Increased sputum production

          -  Increased dyspnea

          -  Increased cough

          -  At least two exacerbations of AECB in the past 12 months

          -  Documented FEV1 less than 80% of predicted

        Exclusion Criteria:

          -  A chest radiograph consistent with pneumonia

          -  Treatment with any systemic antibiotic within the twenty-one days prior to study entry
             or those with a chance of receiving other systemic antibiotics during study
             participation
Clinical trial NCT00702702 (phase 3, status: terminated)
Conditions: uterine fibroids, anemia
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: proellex 25 mg, proellex 50 mg, placebo
SMILES: [H][C@@]12CC[C@](OC(C)=O)(C(=O)COC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H], [H][C@@]12CC[C@](OC(C)=O)(C(=O)COC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    repros stopped study for safety and fda put study on hold because of safety.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Female, between the ages of 18 and 48 years with Body Mass Index (BMI) between 18 and
             39, inclusive;

          -  Anemic, defined as hemoglobin levels less than or equal to 10.5 g/dL and uterine
             fibroid-associated symptoms indicated by a history of excessive menstrual bleeding;

          -  Surgical interventions for uterine fibroids (e.g. hysterectomy or myomectomy) planned
             or anticipated after the study;

          -  Willing to comply with all study procedures, including the endometrial biopsies and
             blood draws for all visits, including Follow-up Visits

        Exclusion Criteria:

          -  Post-menopausal women or women likely to become post-menopausal during the study,
             defined as one or more of the following:

               -  Six months or more (immediately prior to Screening Visit) without a menstrual
                  period, or

               -  Prior hysterectomy, or

               -  Prior bilateral oophorectomy (unilateral oophorectomy is not exclusionary if
                  regular menstruation is occurring);

          -  Females who have undergone a uterine arterial embolization, or endometrial ablation
             therapy (previous myomectomy is acceptable) for any cause;

          -  Documented endometriosis or active pelvic inflammatory disease (PID);

          -  Having a diagnosis, or suspected diagnosis, of carcinoma of the breast or reproductive
             organs;

          -  Known active infection with HIV, Hepatitis A, B or C, Gonorrhea, or Chlamydia;

          -  Use of prohibited concomitant medications:

               1. Depo-Provera use must cease ten months prior to first dose of study drug, or

               2. GnRH agonists use (e.g. Lupron Depot) must cease six months prior to first dose
                  of study drug, or

               3. Oral contraceptive or other hormonal treatments use must cease for 30 days prior
                  to the start of the study
Clinical trial NCT00450970 (phase 3, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: oral satraplatin
SMILES: N.[Cl-].[Cl-].[Pt+4].CC([O-])=O.CC([O-])=O.NC1CCCCC1
Reason stopped: 
    sponsor decided to discontinue study drug development.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic(Stage D2)prostate cancer

          -  Progression after unlimited prior cytotoxic chemotherapy regimens

          -  ECOG Performance status equal/less than 2

          -  Surgical or medical castration

          -  Adequate bone marrow, liver, and renal function

          -  Informed consent

          -  Patients treated with bisphosphonates prior to entry are eligible and should continue
             bisphosphonates therapy while on this trial

        Exclusion Criteria:

          -  Serious concurrent uncontrolled medical disorder

          -  Malignant disease requiring on-going therapy

          -  Prior significant RT/radionuclide therapy

          -  Major GI surgery or GI disease affecting absorption

          -  Disease where corticosteroids are contraindicated

          -  Brain metastases

          -  Poorly-controlled or uncontrolled insulin-dependent diabetes
Clinical trial NCT00134264 (phase 3, status: terminated)
Conditions: coronary disease, diabetes mellitus
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118, P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: torcetrapib/atorvastatin, atorvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of coronary heart disease or risk equivalents that place the patient at high
             risk for cardiovascular disease events

        Exclusion Criteria:

          -  Women who are pregnant or lactating, or planning to become pregnant.

          -  Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor)
             therapy other than atorvastatin or other concomitant therapy with known lipid altering
             effects on LDL-C and HDL-C including fibrates and nicotinic acid

          -  Subjects taking any drugs known to be associated with an increased risk of myositis in
             combination with HMG-CoA reductase inhibitors

          -  Subjects with any other medical condition or laboratory abnormality which could affect
             subject safety, preclude evaluationof response, or render unlikely that the subject
             would complete the study
Clinical trial NCT00324298 (phase 3, status: completed)
Conditions: drug/agent toxicity by tissue/organ, testicular germ cell tumor
ICD codes: T86.91, T86.92, T86.93, Z52.9, Z94.89, Z94.9, T86.90, E29.0, E29.1, E29.8, E29.9, E89.5, N50.811, N50.812
Drugs: cisplatin, etoposide
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of metastatic germ cell cancer of the testes

               -  Good-prognosis disease

          -  Eligible for treatment with bleomycin, etoposide, and cisplatin

        PATIENT CHARACTERISTICS:

          -  Creatinine clearance ≥ 60 mL/min

          -  No other prior or concurrent malignancy except basal cell skin cancer

          -  No other major systemic illness

          -  No impaired respiratory function, including any of the following:

               -  Shortness of breath on minimal exertion

               -  Hypoxia at rest

          -  Carbon monoxide transfer, total lung capacity, and FEV_1 > 60% of predicted

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy
Clinical trial NCT00559585 (phase 3, status: completed)
Conditions: rheumatoid arthritis (ra)
ICD codes: M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, M06.021
Drugs: subcutaneous (sc) abatacept, intravenous (iv) abatacept
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Subjects who are considered methotrexate inadequate responders

          -  10 or more swollen joints (66 joint count) and 12 or more tender joints (68 joint
             count)

        Exclusion Criteria:

          -  Subjects who failed one or multiple anti-tumor necrosis factor (TNF) therapies

          -  Subjects who meet diagnostic criteria for any other rheumatic disease (e.g., lupus
             erythematous)

          -  Subjects with active vasculitis of a major organ system (except for subcutaneous
             rheumatoid nodules)

          -  Subjects with severe chronic or recurrent bacterial infections

          -  Subjects who have received treatment with rituximab

        An Anti-TNF Failure Sub-study was initiated (recruited separately from Main study) using
        the same treatment as the Main study in order to assess the immunogenicity and safety in
        the Anti-TNF Failure population. The Sub-study terminated due to low recruitment and
        participants were permitted to roll into the LT Open Label Period.
Clinical trial NCT00095173 (phase 3, status: completed)
Conditions: juvenile rheumatoid arthritis
ICD codes: M08.08, M08.48, M08.011, M08.012, M08.019, M08.021, M08.022
Drugs: abatacept, placebo, abatacept
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Juvenile Rheumatoid Arthritis or Juvenile Idiopathic Arthritis;

          -  Current active arthritis;

          -  Failed treatment with at least one disease modifying anti-rheumatic drug (DMARD);

          -  Subjects must discontinue use of any DMARD other than methotrexate prior to the first
             dose of study medication

        Exclusion Criteria:

          -  Presence of infection or history of frequent acute or chronic infections;

          -  Joint replacement surgery required during the study or history of surgery on more than
             5 joints;

          -  Live vaccines within 3 months of the first dose of study medication;

          -  Unresolved serious bacterial infection or chronic bacterial infection;

          -  Subjects who currently have intermittent fever due to JRA/JIA, rheumatoid rash,
             hepato-splenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.
Clinical trial NCT00489827 (phase 3, status: completed)
Conditions: coronary artery bypass, myocardial ischemia, myocardial infarction, coronary artery disease
ICD codes: T82.212S, T82.213S, T82.211S, T82.212A, T82.212D, T82.213A, T82.213D, I25.6, P29.4, I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8, I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: intravenous infusion of saline
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  surgery for unstable coronary artery disease (unstable angina, non-STEMI)

          -  accepted for surgery < 2 weeks after STEMI

          -  coronary surgery for indications above performed with or without cardiopulmonary
             bypass

          -  coronary surgery for indications above with or without simultaneous valve procedure

        Exclusion Criteria:

          -  informed consent not possible because of critical condition or other reason

          -  preoperative use of inotropes or mechanical circulatory assist

          -  preoperative dialysis

          -  redo-procedure

          -  unexpected intraoperative finding / event that increased the dignity of the procedure
             to overshadow the originally planned operation

          -  body weight > 125 kg

          -  food allergy known to have caused flush, rash or asthma
Clinical trial NCT00322153 (phase 3, status: completed)
Conditions: dementia of the alzheimer's type
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: memantine er, placebo
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ambulatory patients aged >/= 50 years

          -  Diagnostic evidence of probable Alzheimer's disease consistent with criteria from the
             National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's
             Disease and Related Disorders Association (NINCDS-ADRDA) and the Diagnostic and
             Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

          -  Confirmatory magnetic resonance imaging (MRI) or computed tomographic (CT) scan within
             the prior 12 months.

          -  Mini-Mental State Examination (MMSE) scores >/= 3 and </= 14 at Screening (Visit 1)
             and Baseline (Visit 2)

          -  Ongoing daily acetylcholinesterase inhibitor (AChEI) therapy at a stable dose for at
             least 3 months prior to Screening (Visit 1). It is preferred that patients continue to
             receive the same AChEI therapy for the duration of the study.

        Exclusion Criteria:

          -  Patients with a modified Hachinski Ischemia Score greater than 4 at Screening.

          -  Patients who have taken memantine within one month of Screening (Visit 1)

          -  Patients who have a known hypersensitivity to memantine, neramexane, rimantadine, or
             amantadine.

          -  Patients whose AChEI therapy is likely to be interrupted or discontinued during the
             course of the study.

          -  Patients who are receiving therapy with more than one AChEI.

          -  Patients with computed tomography (CT) or magnetic resonance imaging (MRI) evidence of
             hydrocephalus, stroke, a space-occupying lesion, cerebral infection, or any clinically
             significant central nervous system disease other than Alzheimer's disease.

          -  Patients with a DSM-IV Axis I disorder other than Alzheimer's disease, including
             amnestic disorders, schizophrenia or schizoaffective disorder, bipolar disorder,
             current major depressive episode, psychosis, panic, or post-traumatic stress disorder.

          -  Patients who, in the clinician's judgement, are likely to be placed in a nursing home
             within the next 6 months.

          -  Patients who had evidence of other neurological disorders that included, but were not
             limited to, stroke, Parkinson's disease, seizure disorder, or head injury with loss of
             consciousness within the prior 5 years

          -  Patients who had dementia that was complicated by other organic disease

          -  Patients who had dementia complicated by the presence of predominant delusions
Clinical trial NCT00308737 (phase 3, status: completed)
Conditions: diabetes, type 1, diabetes, type 2
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: technosphere® insulin inhalation powder, usual care
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  For All Subjects:

               -  Nonsmoking

               -  Body mass index <42 kg/m2

               -  FEV1 greater than or equal to 70% of predicted , DLco and TLC greater than or
                  equal to 80% of predicted at screening,

               -  No abnormalities in screening pulmonary radiology

          -  For Subjects with diabetes mellitus:

               -  Type 1 or type 2 diabetes for at least 2 years

               -  HbA1c greater than or equal to 6.6 % and less than or equal to 12.0 %

          -  For Subjects without abnormalities in glucose control:

               -  No history of diabetes

               -  Normal results from a formal glucose tolerance test

        Exclusion Criteria:

          -  History of chronic obstructive pulmonary disease, asthma, or other significant
             pulmonary disease

          -  Significant renal, hepatic, or cardiac disease

          -  Women who are pregnant, lactating, or planning on becoming pregnant

          -  Subjects who have participated in studies of other investigational drugs within the
             previous 3 months

          -  Evidence of severe complications of diabetes
Clinical trial NCT00127530 (phase 3, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: fampridine-sr, placebo
SMILES: NC1=CC=NC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a confirmed diagnosis of multiple sclerosis

          -  Are able to walk with or without an assistive device

        Exclusion Criteria:

          -  Pregnancy, breastfeeding or females of childbearing potential not using adequate birth
             control

          -  Participating in other investigational drug trials

          -  A medical history or clinical findings that preclude entry into the study

          -  A medication history that precludes entry into the study

          -  Previously treated with 4-aminopyridine (4-AP)
Clinical trial NCT01057758 (phase 3, status: terminated)
Conditions: pneumonia
ICD codes: A01.03, A02.22, A54.84, B01.2, B06.81, B77.81, J12.0
Drugs: simvastatin, placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    stopped for futility
  
Eligibility criteria:

        Inclusion Criteria:

          -  Duration of mechanical ventilation > 48 h

          -  First episode of suspicion of VAP with a Clinical Pulmonary Infection Score modified ≥
             5

          -  BAL, plugged telescopic catheter and/or tracheal aspirates quantitative cultures
             performed prior administration of antibiotics

          -  Informed consent

        Exclusion Criteria:

          -  Statin treatment received under mechanical ventilation

          -  Age less than 18 years

          -  Pregnancy

          -  Unable to receive or unlikely to absorb enteral study drug

          -  Patient, surrogate, or physician not committed to full support ).

          -  Moribund patient with a SAPS II score > 75

          -  Simvastatin specific exclusions Allergy or intolerance to statins Physician insistence
             for the use or avoidance of statins during the current hospitalization CK , ALT or AST
             > 5 times the upper limit of normal Receiving cyclosporine, gemfibrozil, lopinavir,
             ritonavir itraconazole, kétoconazole, érythromycine, clarithromycine, télithromycine,
             néfazodone, verapamil, diltiazem

          -  Severe chronic liver disease
Clinical trial NCT00057564 (phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: a (thalidomide + dexamethasone), b (placebo + dexamethasone)
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Active Multiple Myeloma Stage II or III Durie Salmon

          -  Measurable levels of myeloma paraprotein in serum (≥1.0g/dL) or urine (≥ 0.2g excreted
             in a 24-hour collection sample)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2

          -  Women of child bearing potential must agree to abstain for heterosexual intercourse or
             use 2 methods of contraception, one effective (for example hormonal or tubal ligation)
             and one barrier (for example latex condom, diaphragm)

          -  Males must agree to use barrier contraception (latex condoms) when engaging in
             reproductive activity

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Peripheral neuropathy ≥ to grade 2 of the NCI CTC.

          -  Prior history of malignancy unless subject has been free of disease for ≥ 3 years

          -  Lab abnormality: Absolute neutrophil count (ANC) <1,000 cells/mm^3 (1.0 x 10^9/L)

          -  Lab abnormality: Platelet count <50,000/mm^3 (50.0 x 10^9/L)

          -  Lab abnormality: Serum creatinine >3.0 mg/dL (265 µmol/L)

          -  Lab abnormality: Serum glutamic oxaloacetic transaminase (SGOT) /Aspartate
             aminotransferase (AST) or Serum glutamic pyruvic transaminase (SGPT)/Alanine
             transaminase (ALT) >3.0 x upper limit of normal (ULN)

          -  Lab abnormality: Serum total bilirubin > 2.0 mg/dL (34 µmol/L)
Clinical trial NCT00662688 (phase 3, status: terminated)
Conditions: chemotherapeutic agent toxicity, pancreatic cancer, thromboembolism
ICD codes: C25.3, O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: daltéparine, chemotherapy at the investigator's discretion
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    recruitment prematurely stopped due to a lack of eligible patients.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the pancreas

               -  Metastatic disease

               -  Not amenable to treatment

               -  No localized or locally advanced disease

          -  Measurable disease (metastatic or primary tumor) defined as ≥ 2 cm by CT scan or ≥ 1
             cm by spiral CT scan or MRI

          -  No progressive thrombo-embolic disease

          -  No adenocarcinoma of the biliary tract or ampulla of Vater

          -  No known CNS metastases

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Life expectancy > 12 weeks

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL

          -  Alkaline phosphatase < 5 times normal

          -  Bilirubin < 1.5 times normal

          -  Creatinine < 1.5 times normal

          -  Creatinine clearance < 30 mL/min

          -  Pain controlled or stabilized via analgesic therapy

          -  Affiliation with social security system

          -  Not pregnant or nursing

          -  No controlled or uncontrolled jaundice

          -  No contraindication to study drugs

          -  No cardiovascular accident (myocardial infarction, cerebral vascular accident) within
             the past 6 months

          -  No serious cardiac and/or respiratory disease

          -  No other cancer in the past 5 years except the following cancers, provided they have
             been completely resected:

               -  Skin cancer

               -  Localized melanoma

               -  Carcinoma in situ of the cervix

          -  No history of thrombophilia

          -  No history of heparin-induced thrombocytopenia

          -  No uncontrolled or persistent hypercalcemia

          -  No psychological, familial, social, and/or geographical condition that precludes
             participation in the study

        PRIOR CONCURRENT THERAPY:

          -  No prior hematologic therapy for metastatic disease

          -  No prior abdominal radiotherapy

          -  No concurrent corticosteroids as anti-emetic therapy

          -  No other concurrent anticoagulation